A new glucagon and GLP-1 co-agonist eliminates obesity in rodents-Reference-Cited by-同舟云学术

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

Published:2009-07-13 Issue:10 Volume:5 Page:749-757
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Day Jonathan W,Ottaway Nickki,Patterson James T,Gelfanov Vasily,Smiley David,Gidda Jas,Findeisen Hannes,Bruemmer Dennis,Drucker Daniel J,Chaudhary Nilika,Holland Jenna,Hembree Jazzminn,Abplanalp William,Grant Erin,Ruehl Jennifer,Wilson Hilary,Kirchner Henriette,Lockie Sarah Haas,Hofmann Susanna,Woods Stephen C,Nogueiras Ruben,Pfluger Paul T,Perez-Tilve Diego,DiMarchi Richard,Tschöp Matthias H

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/nchembio.209.pdf

Reference34 articles.

1. Ogden, C.L. et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 295, 1549–1555 (2006).

2. Neovius, M. & Narbro, K. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int. J. Obes. 32, 1752–1763 (2008).

3. Cvetkovic, R.S. & Plosker, G.L. Exenatide - a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 67, 935–954 (2007).

4. Gutniak, M., Orskov, C., Holst, J.J., Ahren, B. & Efendic, S. Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes-mellitus. N. Engl. J. Med. 326, 1316–1322 (1992).

5. Roth, J.D. et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. USA 105, 7257–7262 (2008).

Cited by 528 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weight Loss Pharmacotherapy;Gastrointestinal Endoscopy Clinics of North America;2024-10

2. Effects of Once-Weekly Subcutaneous Retatrutide on Weight and Metabolic Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Metabolism Open;2024-09

3. GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-08-22

4. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management;Nature Metabolism;2024-08-19

5. The role of incretin receptor agonists in the treatment of obesity;Diabetes, Obesity and Metabolism;2024-07-29